Globalworld globe
United Kingdom
North America
  • facebook
  • linkedin
Medical Developments International
  • Home
  • Products
    • Asthma & COPD
    • Penthrox
    • Medical Devices
    • Veterinary
  • About
    • Distributor Information
    • Careers
    • Associations
  • Investors/Media
    • Financial Reports
    • Board of Directors/Management
    • Corporate Governance
    • Media Centre
    • Diversity Policy
    • Share Trading Policy
  • Healthcare Professionals
  • Contact

News

MVP signs major deal with CSIRO

Oct 28, 2016Mark EdwardsNews

28 October 2016

MVP signs major deal with CSIRO on exclusive rights for some key drugs

Medical Developments International Limited (ASX: MVP) is delighted to announce it has signed a Term Sheet with Australia?s preeminent science and research body the Commonwealth Scientific and Industrial Research Organisation (CSIRO), to conduct a Research and Development program into new manufacturing technologies for pharmaceutical products. Final documentation is expected to be completed by 31 December 2016.

For details relating to the full ASX release, please click on the following link: MVP signs major deal with CSIRO

Contact Us

for information on our range of products

Find a distributor

in our global network

Investors

invest in a company with
innovative foresight

News

  • Appointment of Non-Executive Director – Mary Sontrop

    5 March 2021 ASX ANNOUNCE...

  • FY21 Half Year Report and Accounts

    26 February 2021 ASX ANNO...

  • MVP Completes $25m Placement

    14 December 2020 ASX ANNO...

Healthcare Professional Registration

Login to access healthcare professional resources



Remember Me


Forgot password? | Register

Medical Developments International

Address:
4 Caribbean Drive, Scoresby,
Victoria, 3179
Australia
Phone: +61 3 9547 1888
Email: mdi@medicaldev.com
ABN: 14 106 340 667
For Medical Enquiries:

Phone: 1800 PENTHROX (1800 736 847)
Email: medinf@medicaldev.com

Email Newsletter

Sign up to our newsletter to receive MDI corporate, investor  & media news.